Streetbeat News

Stock Prices

DELL

SMCI

Dell Technologies Inc (NYSE:DELL) shares are trading higher following positive analyst coverage from JPMorgan and Citigroup. JPMorgan analyst Samik Chatterjee maintained an Overweight rating and raised the price target to $160, while Citigroup analyst Asiya Merchant maintained a Buy rating and raised revenue estimates. Dell shares have been underperforming recently but are seeing a lift due to these positive analyst actions.

Portfolio Pulse from Adam Eckert

August 15, 2024 | 4:06 pm

CGNT

Cognyte Software Ltd. (NASDAQ:CGNT) announced that a national security agency in the Asia-Pacific region has exercised a $4 million option to expand its investigative analytics solutions. This expansion will help the agency manage growing data volumes and enhance public safety.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 4:05 pm

CRM

Salesforce, Inc. (NYSE:CRM) shares are moving higher on Thursday ahead of its 2024 fiscal year second quarter earnings release on Aug. 28. Analysts estimate EPS of $2.36 and revenue of $9.23 billion. Salesforce has a strong record of beating EPS estimates, although it missed revenue estimates last quarter for the first time in years. The stock is trading above its 50-day moving average and is currently at $261.02.

Portfolio Pulse from Dylan Berman

August 15, 2024 | 4:03 pm

STLD

Analyst ratings for Steel Dynamics (NASDAQ:STLD) over the past three months show mixed sentiments, with most analysts being indifferent. The average 12-month price target has increased slightly to $137.6. Recent actions by analysts include both raises and lowers in ratings and price targets.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 4:01 pm

PACS

Analysts have provided mixed ratings for PACS Group (NYSE:PACS) over the past quarter, with a majority leaning bullish. The average 12-month price target has increased by 15% to $39.33. Key analysts have raised their ratings and price targets, reflecting positive sentiment towards the company's future performance. Despite strong revenue growth, PACS Group faces challenges with profitability and debt management.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 4:00 pm

SRPT

Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 28 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target is $185.0, with a high of $235.00 and a low of $128.00. Recent analyst actions include both raises and lowers in ratings and price targets, reflecting diverse opinions on the company's future performance.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 4:00 pm

LVS

In the past three months, 12 analysts have provided ratings on Las Vegas Sands (NYSE:LVS), with a mix of bullish to bearish sentiments. The average 12-month price target is now $54.83, down from $59.25. Analysts from firms like Wells Fargo, Deutsche Bank, and Morgan Stanley have lowered their price targets. Despite a 7.46% decline in the average price target, Las Vegas Sands shows strong financial performance with notable revenue growth, net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 4:00 pm

INTC

NVDA

SPY

TSM

VOO

Nvidia Corp (NASDAQ:NVDA) stock is trading higher on Thursday due to a fallout in AI chip production discussions between SoftBank Group Corp (OTC:SFTBF) and Intel Corp (NASDAQ:INTC). SoftBank is now turning to Taiwan Semiconductor Manufacturing Co (NYSE:TSM), a key Nvidia supplier. Intel's financial struggles, including a $7 billion operating loss, contributed to the failed deal. Nvidia's stock has been volatile but is up over 176% in the last 12 months. Investors can gain exposure to Nvidia through Vanguard S&P 500 ETF (NYSE:VOO) and SPDR S&P 500 (NYSE:SPY).

Portfolio Pulse from Anusuya Lahiri

August 15, 2024 | 3:59 pm

PNC

PNC Financial shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $185 to $200.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 3:59 pm

TSBX

Turnstone Biologics Corp. (NASDAQ:TSBX) released initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite-stable colorectal cancer (MSS mCRC). The data showed a 25% overall response rate and a 50% disease control rate among four evaluable patients. The company is now focusing on high unmet medical need cancers, including colorectal cancer, head and neck cancer, and uveal melanoma. Despite the promising data, TSBX stock is down 57.53% to 93 cents.

Portfolio Pulse from Vandana Singh

August 15, 2024 | 3:57 pm